Apitope is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves’ disease, allergies and organ transplant rejection.
The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system.
Apitope’s approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance.
Apitope has shown that not all peptide epitopes can suppress disease and they must behave as Apitopes™ - Antigen Processing Independent epiTOPES - in order to be effective therapeutic vaccines. The Company’s patented, leading edge, high speed discovery platform enables it to identify and design innovative peptide-based therapies and diagnostics and it has an impressive pipeline of products in development.
Apitope’s strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds.
The company’s lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies.